Why Did Suboxone ANDA Applicant Forfeit 180-Day Exclusivity? US FDA's Answer Sets New Policy
Executive Summary
Agency reinterprets definition of "first applicant" and applies "failure to market" forfeiture provision of MMA; court halts sales of Dr. Reddy's generic.
You may also be interested in...
Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis
Complaint challenges agency's revised definition of "first applicant," which does not require notice of Paragraph IV certification to obtain exclusivity.
Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis
Complaint challenges agency's revised definition of "first applicant," which does not require notice of Paragraph IV certification to obtain exclusivity.
Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade
Suboxone market share has declined with the at-risk launch of Dr. Reddy’s generic competitor, while Indivior awaits a court decision on a requested temporary restraining order against the launch.